Phosphorylation and polyubiquitination of transforming growth factor β-activated kinase 1 are necessary for activation of NF-κB by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 1980-1993

  Bottero, Virginie ^a   Kerur, Nagaraj ^a   Sadagopan, Sathish ^a   Patel, Kinjan ^a   Sharma Walia, Neelam ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; G PROTEIN COUPLED RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUBULIN;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; UBIQUITINATION;

HEK293 CELLS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; MAP KINASE KINASE KINASES; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRAL PROTEINS;

HUMAN HERPESVIRUS 8;

EID: 79551717471     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01911-10     Document Type: Article

References (85)

1. Adhikari, A., M. Xu, and Z. J. Chen. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26:3214-3226.
2. Arvanitakis, L., E. Geras-Raaka, A. Varma, M. C. Gershengorn, and E. Cesarman. 1997. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385:347-350.
3. Bais, C., et al. 1998. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89. (Pubitemid 28079220)
4. Bais, C., et al. 2003. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3:131-143. (Pubitemid 37443386)
5. Bassères, D. S., and A. S. Baldwin. 2006. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830.
6. Bottero, V., V. Imbert, C. Frelin, J. L. Formento, and J. F. Peyron. 2003. Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression. Mol. Diagn. 7:187-194.
7. Cai, X., et al. 2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 102:5570-5575.
8. Cannon, M. 2007. The KSHV and other human herpesviral G protein-coupled receptors. Curr. Top. Microbiol. Immunol. 312:137-156.
9. Cannon, M., N. J. Philpott, and E. Cesarman. 2003. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J. Virol. 77:57-67. (Pubitemid 36004946)
10. Cannon, M. L., and E. Cesarman. 2004. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23:514-523. (Pubitemid 38175006)
11. Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191.
12. Chen, M., A. E. Rose, N. Doudican, I. Osman, and S. J. Orlow. 2009. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol. Cancer Res. 7:1946-1953.
13. Chen, Z. J. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7:758-765.
14. Chen, Z. J., V. Bhoj, and R. B. Seth. 2006. Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ. 13:687-692.
15. Chiou, C. J., et al. 2002. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J. Virol. 76:3421-3439.
16. Courtois, G., and T. D. Gilmore. 2006. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25:6831-6843.
17. Couty, J. P., E. Geras-Raaka, B. B. Weksler, and M. C. Gershengorn. 2001. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. J. Biol. Chem. 276:33805-33811.
18. Dadke, D., B. H. Fryer, E. A. Golemis, and J. Field. 2003. Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res. 63:8837-8847. (Pubitemid 38064063)
19. Deng, L., et al. 2000. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-361.
20. Dutta, J., Y. Fan, N. Gupta, G. Fan, and C. Gelinas. 2006. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800-6816. (Pubitemid 44657853)
21. Eliopoulos, A. G., and L. S. Young. 2001. LMP1 structure and signal transduction. Semin. Cancer Biol. 11:435-444.
22. Fan, Y., et al. 2010. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta- induced IKK/NF-kappaB and JNK/AP-1 activation. J. Biol. Chem. 285:5347-5360.
23. Ganem, D. 2007. Kaposi's sarcoma-associated herpesvirus, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
24. Gerondakis, S., et al. 2006. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 25:6781-6799. (Pubitemid 44657852)
25. Glaunsinger, B., and D. Ganem. 2004. Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis. J. Exp. Med. 200:391-398.
26. Gohda, J., et al. 2007. HTLV-1 Tax-induced NFkappaB activation is independent of Lys-63-linked-type polyubiquitination. Biochem. Biophys. Res. Commun. 357:225-230.
27. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
28. Grisotto, M. G., et al. 2006. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest. 116:1264-1273.
29. Guo, H. G., et al. 2003. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J. Virol. 77:2631-2639.
30. He, D., et al. 2009. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9:343.
31. Huang, T. T., S. L. Feinberg, S. Suryanarayanan, and S. Miyamoto. 2002. The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Mol. Cell. Biol. 22:5813-5825.
32. Idris, A. I., et al. 2009. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 8:2339-2347.
33. Israel, A. 2010. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harbor Perspect. Biol. 2:a000158.
34. Kim, D. H., et al. 2009. Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur. J. Clin. Invest. 39:819-827.
35. Lamb, A., et al. 2009. Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep. 10:1242-1249.
36. Lee, D. F., and M. C. Hung. 2008. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 14:5656-5662.
37. Lee, J. H., et al. 2006. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem. Pharmacol. 72:1311-1321.
38. Liu, C., G. Sandford, G. Fei, and J. Nicholas. 2004. Galpha protein selectivity determinant specified by a viral chemokine receptor-conserved region in the C tail of the human herpesvirus 8 g protein-coupled receptor. J. Virol. 78:2460-2471. (Pubitemid 38228939)
39. Lluis, J. M., et al. 2010. TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL. PLoS One 5:e8620.
40. Martin, D., R. Galisteo, Y. Ji, S. Montaner, and J. S. Gutkind. 2008. An NF-kappaB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 27:1844-1852.
41. Martín, M. J., et al. 2007. The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis. J. Biol. Chem. 282:34510-34524.
42. Miyoshi, H., U. Blomer, M. Takahashi, F. H. Gage, and I. M. Verma. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72:8150-8157.
43. Montaner, S., et al. 2003. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3:23-36. (Pubitemid 37443889)
44. Montaner, S., A. Sodhi, S. Pece, E. A. Mesri, and J. S. Gutkind. 2001. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 61:2641-2648.
45. Montaner, S., et al. 2004. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 104:2903-2911. (Pubitemid 39434978)
46. Nam, N. H. 2006. Naturally occurring NF-kappaB inhibitors. Mini Rev. Med. Chem. 6:945-951.
47. Ninomiya-Tsuji, J., et al. 1999. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252-256.
48. Pang, X., et al. 2010. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70:1951-1959.
49. Pati, S., et al. 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J. Virol. 75:8660-8673. (Pubitemid 32768970)
50. Polson, A. G., D. Wang, J. DeRisi, and D. Ganem. 2002. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus. Cancer Res. 62:4525-4530. (Pubitemid 34827318)
51. Rayet, B., and C. Gelinas. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947.
52. Rosenkilde, M. M., T. N. Kledal, H. Brauner-Osborne, and T. W. Schwartz. 1999. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J. Biol. Chem. 274:956-961.
53. Sakurai, H., H. Miyoshi, J. Mizukami, and T. Sugita. 2000. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett. 474:141-145. (Pubitemid 30330823)
54. Samols, M. A., J. Hu, R. L. Skalsky, and R. Renne. 2005. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:9301-9305. (Pubitemid 40934841)
55. Schwarz, M., and P. M. Murphy. 2001. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J. Immunol. 167:505-513.
56. Sethi, G., K. S. Ahn, M. K. Pandey, and B. B. Aggarwal. 2007. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109:2727-2735.
57. Sharma-Walia, N., et al. 2010. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 6:e1000777.
58. Shelby, B. D., et al. 2007. Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells. Virol. J. 4:87.
59. Shepard, L. W., et al. 2001. Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA. J. Biol. Chem. 276:45979-45987.
60. Shibuya, H., et al. 1998. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J. 17:1019-1028. (Pubitemid 28077656)
61. Shim, J. H., et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19:2668-2681.
62. Skaug, B., X. Jiang, and Z. J. Chen. 2009. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 78:769-796.
63. Sodhi, A., et al. 2000. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60:4873-4880.
64. Soni, V., E. Cahir-McFarland, and E. Kieff. 2007. LMP1 TRAFficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597:173-187.
65. Sorrentino, A., et al. 2008. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10:1199-1207.
66. Staskus, K. A., et al. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:715-719. (Pubitemid 26412345)
67. Suzuki, S., et al. 2007. Constitutive activation of TAK1 by HTLV-1 tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-kappaB. J. Biol. Chem. 282:25177-25181.
68. Takatsu, Y., et al. 2000. TAK1 participates in c-Jun N-terminal kinase signaling during Drosophila development. Mol. Cell. Biol. 20:3015-3026.
69. Thiefes, A., et al. 2005. Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor target genes. J. Biol. Chem. 280:27728-27741.
70. Tiscornia, G., O. Singer, and I. M. Verma. 2006. Production and purification of lentiviral vectors. Nat. Protoc. 1:241-245.
71. Uemura, N., et al. 2006. TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. J. Biol. Chem. 281:7863-7872.
72. Vallabhapurapu, S., and M. Karin. 2009. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27:693-733.
73. Vart, R. J., et al. 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 67:4042-4051. (Pubitemid 46815049)
74. Wan, J., et al. 2004. Elucidation of the c-Jun N-terminal kinase pathway mediated by Epstein-Barr virus-encoded latent membrane protein 1. Mol. Cell. Biol. 24:192-199.
75. Wang, C., et al. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-351. (Pubitemid 32694385)
76. Wertz, I. E., and V. M. Dixit. 2010. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harbor Perspect. Biol. 2:a003350.
77. Wu, L., H. Nakano, and Z. Wu. 2006. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappaB through TRAF6 and TAK1. J. Biol. Chem. 281:2162-2169.
78. Wu, X., and S. C. Sun. 2007. Retroviral oncoprotein Tax deregulates NF-kappaB by activating Tak1 and mediating the physical association of Tak1-IKK. EMBO Rep. 8:510-515.
79. Yamaguchi, K., et al. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270:2008-2011. (Pubitemid 26097194)
80. Yang, H., D. Chen, Q. C. Cui, X. Yuan, and Q. P. Dou. 2006. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66:4758-4765.
81. Yang, T. Y., et al. 2000. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191:445-454.
82. Yu, Q., et al. 2008. HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein. Biochem. Biophys. Res. Commun. 365:189-194.
83. Zhang, D., et al. 2000. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6:556-563.
84. Zhong, W., H. Wang, B. Herndier, and D. Ganem. 1996. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad. Sci. U. S. A. 93:6641-6646.
85. Zhou, Y., et al. 2010. HBx-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes. J. Biol. Chem. 285:12159-12168.